Literature DB >> 24189842

Immune mechanisms in medium and large-vessel vasculitis.

Cornelia M Weyand1, Jörg J Goronzy.   

Abstract

Vasculitis of the medium and large arteries, most often presenting as giant cell arteritis (GCA), is an infrequent, but potentially fatal, type of immune-mediated vascular disease. The site of the aberrant immune reaction, the mural layers of the artery, is strictly defined by vascular dendritic cells, endothelial cells, vascular smooth muscle cells and fibroblasts, which engage in an interaction with T cells and macrophages to, ultimately, cause luminal stenosis or aneurysmal wall damage of the vessel. A multitude of effector cytokines, all known as critical mediators in host-protective immunity, have been identified in vasculitic lesions. Two dominant cytokine clusters--the IL-6-IL-17 axis and the IL-12-IFN-γ axis--have been linked to disease activity. These two clusters seem to serve different roles in the vasculitic process. The IL-6-IL-17 cluster is highly responsive to standard corticosteroid therapy, whereas the IL-12-IFN-γ cluster is resistant to steroid-mediated immunosuppression. The information exchange between vascular and immune cells and stabilization of the vasculitic process involves members of the Notch receptor and ligand family. Focusing on elements in the tissue context of GCA, instead of broadly suppressing host immunity, might enable a more tailored therapeutic approach that avoids unwanted adverse effects of aggressive immunosuppression.

Entities:  

Mesh:

Year:  2013        PMID: 24189842      PMCID: PMC4277683          DOI: 10.1038/nrrheum.2013.161

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  107 in total

Review 1.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

2.  Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease.

Authors:  A D Wagner; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis.

Authors:  Francesco Ciccia; Riccardo Alessandro; Aroldo Rizzo; Simona Principe; Francesca Raiata; Alberto Cavazza; Giuliana Guggino; Antonina Accardo-Palumbo; Luigi Boiardi; Angelo Ferrante; Alfonso Principato; Annarita Giardina; Giacomo De Leo; Carlo Salvarani; Giovanni Triolo
Journal:  Arthritis Rheum       Date:  2011-07

4.  Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Authors:  S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-11       Impact factor: 4.794

5.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.

Authors:  N E Roche; J W Fulbright; A D Wagner; G G Hunder; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1993-09

6.  Vessel-specific Toll-like receptor profiles in human medium and large arteries.

Authors:  Olga Pryshchep; Wei Ma-Krupa; Brian R Younge; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2008-09-02       Impact factor: 29.690

7.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Authors:  J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

Review 8.  IL-22, not simply a Th17 cytokine.

Authors:  Sascha Rutz; Céline Eidenschenk; Wenjun Ouyang
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

9.  The role of non-hematopoietic stromal cells in the persistence of inflammation.

Authors:  Francesca Barone; Saba Nayar; Chris D Buckley
Journal:  Front Immunol       Date:  2013-01-14       Impact factor: 7.561

10.  Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach.

Authors:  Alexis Régent; Hanadi Dib; Kim H Ly; Christian Agard; Mathieu C Tamby; Nicolas Tamas; Babette Weksler; Christian Federici; Cédric Broussard; Loïc Guillevin; Luc Mouthon
Journal:  Arthritis Res Ther       Date:  2011-06-28       Impact factor: 5.156

View more
  112 in total

Review 1.  [Management of polymyalgia rheumatica and large vessel vasculitis].

Authors:  B Hellmich
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

2.  [Brain stem infarction, temporal headache, and elevated inflammatory parameters in a 74-year-old man].

Authors:  M Gehlen; M Schwarz-Eywill; N Schäfer; A Pfeiffer; H Bösenberg; A Maier; C Hinz
Journal:  Internist (Berl)       Date:  2016-06       Impact factor: 0.743

3.  The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel
Journal:  J Autoimmun       Date:  2019-07-15       Impact factor: 7.094

4.  [Tocilizumab in giant cell arteritis].

Authors:  J Pflugfelder
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

Review 5.  Immune checkpoint dysfunction in large and medium vessel vasculitis.

Authors:  Ryu Watanabe; Hui Zhang; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

Review 6.  Macrophages in vascular inflammation--From atherosclerosis to vasculitis.

Authors:  Tsuyoshi Shirai; Marc Hilhorst; David G Harrison; Jörg J Goronzy; Cornelia M Weyand
Journal:  Autoimmunity       Date:  2015-03-26       Impact factor: 2.815

7.  The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway.

Authors:  Zhenke Wen; Yi Shen; Gerald Berry; Farhad Shahram; Yinyin Li; Ryu Watanabe; Yaping Joyce Liao; Jörg J Goronzy; Cornelia M Weyand
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

8.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

Review 9.  Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis.

Authors:  Ryu Watanabe; Ebru Hosgur; Hui Zhang; Zhenke Wen; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Joint Bone Spine       Date:  2016-09-20       Impact factor: 4.929

10.  Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.

Authors:  Bryant R England; Ted R Mikuls; Fenglong Xie; Shuo Yang; Lang Chen; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.